Loading
A phase 1/2 trial of Osimertinib, Pemetrexed, Carboplatin in mesothelioma, run by Vivace Therapeutics, Inc, now recruiting.
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04665206 by Vivace Therapeutics, Inc, with 434 participants planned, started 2021-03-24 and due to reach its primary completion in 2029-11-02. Interventions recorded: VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin. Conditions listed: Solid Tumor, Adult, Mesothelioma, NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, Pemetrexed, Carboplatin.
Shares Osimertinib, Pemetrexed, Carboplatin.
Shares Pemetrexed, Carboplatin.
Shares Osimertinib, Pemetrexed, Carboplatin.
Shares Osimertinib, Pemetrexed, Carboplatin.
Shares Osimertinib, Pemetrexed, Carboplatin.
Shares Osimertinib, Pemetrexed, Carboplatin.
Shares Mesothelioma, Pemetrexed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/